Takeda’s Fruquintinib Gains the CHMP’s Positive Opinion for Previously Treated Metastatic Colorectal Cancer
Shots:
- The CHMP has granted positive opinion to the company’s fruquintinib (VEGFR-1, -2 & -3 inhibitor) for previously treated metastatic colorectal cancer (mCRC) adults. Takeda holds its exclusive global rights outside of mainland China, Hong Kong & Macau while HUTCHMED has China rights
- The opinion was based on P-III (FRESCO-2) study assessing fruquintinib + best supportive care (BSC)vs PBO + BSC in previously treated mCRC patients
- TThe study met both 1EPs and 2EPs demonstrating improved OS & PFS with consistent safety profile irrespective of previous studies. The data was published in The Lancet
Ref: Takeda | Image: Takeda
Related News:- The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
